Last reviewed · How we verify
Placebo plus standard therapy
Placebo plus standard therapy provides no active pharmacological intervention beyond the standard treatment already being administered.
At a glance
| Generic name | Placebo plus standard therapy |
|---|---|
| Also known as | Standard therapy |
| Sponsor | RemeGen Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Mechanism of action
This is a control arm used in clinical trials, where patients receive standard-of-care therapy combined with an inert placebo. Any observed clinical benefit derives entirely from the standard therapy itself, allowing researchers to isolate the efficacy of investigational treatments when compared against this control. The placebo component may contribute psychological benefit through the placebo effect.
Approved indications
Common side effects
Key clinical trials
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (PHASE1)
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo plus standard therapy CI brief — competitive landscape report
- Placebo plus standard therapy updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI